XOMA Royalty (XOMA) Competitors $37.59 +0.17 (+0.45%) As of 03:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XOMA vs. XOMAO, MNKD, CLDX, INVA, NVAX, DVAX, OPK, GERN, ZBIO, and RIGLShould you be buying XOMA Royalty stock or one of its competitors? The main competitors of XOMA Royalty include XOMA (XOMAO), MannKind (MNKD), Celldex Therapeutics (CLDX), Innoviva (INVA), Novavax (NVAX), Dynavax Technologies (DVAX), OPKO Health (OPK), Geron (GERN), Zenas BioPharma (ZBIO), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "medical" sector. XOMA Royalty vs. Its Competitors XOMA MannKind Celldex Therapeutics Innoviva Novavax Dynavax Technologies OPKO Health Geron Zenas BioPharma Rigel Pharmaceuticals XOMA Royalty (NASDAQ:XOMA) and XOMA (NASDAQ:XOMAO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership. Does the media refer more to XOMA or XOMAO? In the previous week, XOMA Royalty and XOMA Royalty both had 3 articles in the media. XOMA Royalty's average media sentiment score of 1.23 beat XOMA's score of 0.30 indicating that XOMA Royalty is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XOMA Royalty 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive XOMA 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is XOMA or XOMAO more profitable? XOMA has a net margin of 0.00% compared to XOMA Royalty's net margin of -27.57%. XOMA Royalty's return on equity of 2.63% beat XOMA's return on equity.Company Net Margins Return on Equity Return on Assets XOMA Royalty-27.57% 2.63% 0.97% XOMA N/A N/A N/A Do analysts recommend XOMA or XOMAO? XOMA Royalty presently has a consensus price target of $69.50, suggesting a potential upside of 84.89%. Given XOMA Royalty's stronger consensus rating and higher possible upside, equities research analysts plainly believe XOMA Royalty is more favorable than XOMA.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XOMA Royalty 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33XOMA 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better earnings & valuation, XOMA or XOMAO? XOMA has lower revenue, but higher earnings than XOMA Royalty. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXOMA Royalty$28.49M15.95-$13.82M-$1.55-24.25XOMA$12.77MN/AN/AN/AN/A Do insiders and institutionals hold more shares of XOMA or XOMAO? 95.9% of XOMA Royalty shares are owned by institutional investors. 7.2% of XOMA Royalty shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryXOMA Royalty beats XOMA on 10 of the 11 factors compared between the two stocks. Get XOMA Royalty News Delivered to You Automatically Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XOMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XOMA vs. The Competition Export to ExcelMetricXOMA RoyaltyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$454.46M$3.11B$5.75B$10.27BDividend YieldN/A2.32%5.73%4.60%P/E Ratio-24.2521.4175.1826.37Price / Sales15.95240.50457.0688.69Price / CashN/A44.4425.8129.91Price / Book5.419.6113.256.28Net Income-$13.82M-$53.20M$3.29B$270.67M7 Day Performance6.34%0.18%0.72%2.79%1 Month Performance19.83%4.02%4.58%6.01%1 Year Performance29.71%9.21%73.44%26.05% XOMA Royalty Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XOMAXOMA Royalty4.2144 of 5 stars$37.59+0.5%$69.50+84.9%+29.1%$454.46M$28.49M-24.2510Positive NewsXOMAOXOMAN/A$25.52+0.1%N/A+1.2%$0.00$12.77M0.0010Short Interest ↑MNKDMannKind4.3495 of 5 stars$5.57+0.5%$10.71+92.4%-11.2%$1.70B$285.50M50.64400Positive NewsShort Interest ↓CLDXCelldex Therapeutics2.3896 of 5 stars$23.40+2.3%$46.67+99.4%-44.6%$1.52B$7.02M-7.77150Positive NewsINVAInnoviva4.8418 of 5 stars$20.46-0.1%$42.75+108.9%-2.2%$1.29B$358.71M66.00100Positive NewsAnalyst DowngradeShort Interest ↓NVAXNovavax4.4845 of 5 stars$7.73-2.2%$14.29+84.8%-41.4%$1.28B$1.08B3.391,990Positive NewsDVAXDynavax Technologies4.4564 of 5 stars$9.70-3.6%$24.33+150.9%-15.8%$1.18B$316.27M-21.09350Positive NewsOPKOPKO Health4.4006 of 5 stars$1.42+5.2%$2.75+93.7%-10.8%$1.07B$713.10M-5.682,997GERNGeron3.1294 of 5 stars$1.37-2.1%$4.19+205.7%-71.8%$893.22M$164.45M-10.5470Positive NewsZBIOZenas BioPharma1.0481 of 5 stars$21.51+4.9%$36.67+70.5%N/A$863.68M$5M-6.06N/AHigh Trading VolumeRIGLRigel Pharmaceuticals1.9665 of 5 stars$40.87-1.1%$38.20-6.5%+177.1%$741.53M$179.28M7.55160Positive News Related Companies and Tools Related Companies XOMA Alternatives MannKind Alternatives Celldex Therapeutics Alternatives Innoviva Alternatives Novavax Alternatives Dynavax Technologies Alternatives OPKO Health Alternatives Geron Alternatives Zenas BioPharma Alternatives Rigel Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XOMA) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Royalty Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA Royalty With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XOMA Stock Alerts